亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688176 亚虹医药

已收盘 05-14 15:00:00

{"stockData":{"symbol":"688176","market":"SH","secType":"STK","nameCN":"亚虹医药","latestPrice":7.73,"timestamp":1747206000000,"preClose":7.75,"halted":0,"volume":4210987,"delay":0,"changeRate":-0.0026,"floatShares":378000000,"shares":570000000,"eps":-0.675,"marketStatus":"已收盘","change":-0.02,"latestTime":"05-14 15:00:00","open":7.79,"high":7.81,"low":7.69,"amount":32604000,"amplitude":0.0155,"askPrice":7.74,"askSize":69,"bidPrice":7.73,"bidSize":235,"shortable":0,"etf":0,"ttmEps":-0.675,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747272600000},"marketStatusCode":5,"adr":0,"adjPreClose":7.75,"symbolType":"stock_kcb","openAndCloseTimeList":[[1747186200000,1747193400000],[1747198800000,1747206000000]],"highLimit":8.53,"lowLimit":6.98,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":570000000,"isCdr":false,"pbRate":2.33,"roa":"--","roe":"--","epsLYR":-0.68,"committee":0.155017,"marketValue":4406000000,"turnoverRate":0.0111,"status":1,"afterMarket":{"amount":0,"volume":0,"close":7.73,"buyVolume":0,"sellVolume":0,"time":1747208038030,"indexStatus":"已收盘 05-14 15:30:00","preClose":7.75},"floatMarketCap":2924000000},"requestUrl":"/m/hq/s/688176","defaultTab":"news","newsList":[{"id":"2535743581","title":"亚虹医药-U05月13日遭主力抛售446.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535743581","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535743581?lang=zh_cn&edition=full","pubTime":"2025-05-13 15:21","pubTimestamp":1747120876,"startTime":"0","endTime":"0","summary":"05月13日, 亚虹医药-U股价跌0.39%，报收7.75元，成交金额3404.1万元，换手率1.15%，振幅2.31%，量比0.57。亚虹医药-U今日主力资金净流出446.9万元，连续6日净流出，上一交易日主力净流出351.3万元。该股近5个交易日下跌6.40%，主力资金累计净流出1855.6万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出3618.5万元，其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250513172417a6dd50ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250513172417a6dd50ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2533468125","title":"多家科创板药企迈入商业化新阶段，智翔金泰、亚虹医药营收大增超1000%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533468125","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533468125?lang=zh_cn&edition=full","pubTime":"2025-05-06 11:06","pubTimestamp":1746500760,"startTime":"0","endTime":"0","summary":"多家科创板生物医药企业在2024年和2025年一季度实现了显著的营收增长，其中智翔金泰和亚虹医药表现尤为突出。智翔金泰2024年营收同比增长2384.10%，主要得益于赛立奇单抗注射液（金立希）获批上市，该药物针对中重度斑块状银屑病和强直性脊柱炎适应症，截至2024年末实现销售收入3006.96万元。其他如迪哲医药、荣昌生物、诺泰生物等企业也表现出强劲的增长势头，反映了科创板生物医药企业正逐步迈入商业化新阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050611161994ed798e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050611161994ed798e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","688443","159982"],"gpt_icon":0},{"id":"2532188640","title":"亚虹医药（688176）2025年一季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2532188640","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532188640?lang=zh_cn&edition=full","pubTime":"2025-05-01 06:38","pubTimestamp":1746052709,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亚虹医药发布2025年一季报。根据财报显示，亚虹医药增收不增利。截至本报告期末，公司营业总收入6110.11万元，同比上升151.24%，归母净利润-8353.07万元，同比下降0.82%。本次财报公布的各项数据指标表现一般。目前公司正在积极寻找海外合作伙伴，准备该项美国三期临床试验申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050100004739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2531720599","title":"亚虹医药一季度亏损扩大至8353万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531720599","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531720599?lang=zh_cn&edition=full","pubTime":"2025-04-30 12:04","pubTimestamp":1745985865,"startTime":"0","endTime":"0","summary":"4月29日，亚虹医药公布2025年一季报，公司营业收入为6110万元，同比上升151.2%；归母净利润自去年同期亏损8285万元变为亏损8353万元，亏损额进一步扩大；扣非归母净利润自去年同期亏损9323万元变为亏损8935万元，亏损额有所减少；经营现金流净额为-1.1亿元，同比增长14.5%；EPS为-0.1465元。公司在研发方面的投入占营业收入的比例达到了90.11%，显示出其对新药研发的重视。文章来源：财中社亚虹医药一季度亏损扩大至8353万元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430123913a46d25d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430123913a46d25d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2530943126","title":"亚虹医药及其子公司Baylink关于AI小分子和ADC平台研究成果亮相2025年美国癌症研究协会年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2530943126","media":"亚虹医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530943126?lang=zh_cn&edition=full","pubTime":"2025-04-27 14:15","pubTimestamp":1745734544,"startTime":"0","endTime":"0","summary":"目前该项目已经正式进入IND Enabling阶段，期望在2025年年底前获得临床批件。这些连接子的优势已在多个项目中得到证实，其中领先项目预计将在2026年中期递交IND。BLB-101 在多种抗原阳性癌细胞系中表现出强大的细胞杀伤作用。此外，在非人灵长类动物中，BLB-101表现出良好的耐受性。如以上两款重要在研产品和一个技术平台的成果所示，亚虹医药和其专注ADC的子公司Baylink Biosciences Inc.展现了突出的新药研发实力， 这些药物有望为肿瘤患者带来更多的福音。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427184654a46918d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427184654a46918d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2530886351","title":"亚虹医药：公司正全力组织相关回复工作，加快推进其上市审评审批工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2530886351","media":"证星董秘互动","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530886351?lang=zh_cn&edition=full","pubTime":"2025-04-25 18:30","pubTimestamp":1745577044,"startTime":"0","endTime":"0","summary":"证券之星消息，亚虹医药04月25日在投资者关系平台上答复投资者关心的问题。请回答，谢谢亚虹医药董秘：尊敬的投资人您好！公司于2025年2月下旬收到书面发补通知，根据法规要求在80个工作日予以反馈，公司正全力组织相关回复工作，加快推进其上市审评审批工作，以期尽快获得上市批准。目前公司正在积极寻找海外合作伙伴，准备该项美国三期临床试验申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251834169744e350&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251834169744e350&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2530746589","title":"亚虹医药-U04月25日遭主力抛售153万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530746589","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530746589?lang=zh_cn&edition=full","pubTime":"2025-04-25 15:20","pubTimestamp":1745565648,"startTime":"0","endTime":"0","summary":"04月25日, 亚虹医药-U股价跌3.08%，报收8.18元，成交金额6049万元，换手率1.94%，振幅3.91%，量比0.75。亚虹医药-U今日主力资金净流出153万元，连续4日净流出，上一交易日主力净流出383万元。该股近5个交易日上涨5.14%，主力资金累计净流出2385万元；近20日主力资金累计净流出1854万元，其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425160620a6c7ba06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425160620a6c7ba06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2529525850","title":"亚虹医药-U04月23日遭主力抛售1483万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529525850","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529525850?lang=zh_cn&edition=full","pubTime":"2025-04-23 15:20","pubTimestamp":1745392807,"startTime":"0","endTime":"0","summary":"04月23日, 亚虹医药-U股价跌1.42%，报收8.31元，成交金额9932万元，换手率3.09%，振幅5.34%，量比1.71。亚虹医药-U今日主力资金净流出1483万元，上一交易日主力净流出533万元。该股近5个交易日上涨5.06%，主力资金累计净流出2436万元；近20日主力资金累计净流出870万元，其中净流出天数为12日。|04月23日主力加仓幅度排名||#|股票简称|主力净额占比|#|健尔康|8.43%|#|新天地|7.95%|#|利安科技|7.56%|#|...|...|#5044|亚虹医药-U|-0.47%|亚虹医药-U所在的化学制药行业，今日主力净流出1.78亿元，行业排名28/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423155853a6c4db22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423155853a6c4db22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2529306224","title":"亚虹医药：4月21日召开业绩说明会，包括知名机构正圆投资的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2529306224","media":"证星公司调研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529306224?lang=zh_cn&edition=full","pubTime":"2025-04-22 20:04","pubTimestamp":1745323440,"startTime":"0","endTime":"0","summary":"目前公司正在积极寻找海外合作伙伴，准备该项美国三期临床试验申请。PL-2501通过溶酶体组织蛋白酶触发释放载荷，确保肿瘤微环境特异性杀伤，旁观者效应显著好于MME，预期在CLDN6弱阳性病人也有反应。PL-2501已经完成抗体人源化实验、体内外药效研究及前期食蟹猴安全性实验及可开发性验证实验。PL-2302在以上肿瘤模型中，单药或联合奥拉帕利抗肿瘤活性均优于KSQ-4279，具有成为同类最佳的潜力。PL-2302的临床前研究结果入选2024年美国癌","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042220071194de16e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042220071194de16e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2529823443","title":"亚虹医药-U04月21日主力净流入166万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529823443","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529823443?lang=zh_cn&edition=full","pubTime":"2025-04-21 15:20","pubTimestamp":1745220004,"startTime":"0","endTime":"0","summary":"04月21日, 亚虹医药-U股价涨4.88%，报收8.16元，成交金额7634万元，换手率2.51%，振幅7.46%，量比1.54。亚虹医药-U今日主力资金净流入166万元，上一交易日主力净流出499万元。该股近5个交易日下跌0.49%，主力资金累计净流入166万元；近20日主力资金累计净流入147万元，其中净流入天数为8日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421155954a6c20103&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421155954a6c20103&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2529708598","title":"亚虹医药：销售超额完成目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2529708598","media":"财通证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529708598?lang=zh_cn&edition=full","pubTime":"2025-04-21 00:00","pubTimestamp":1745164800,"startTime":"0","endTime":"0","summary":"销售持续放量，超额完成年初目标。2024 年是亚虹医药首个完整的商业化年度，通过不断优化市场策略及落地执行质量，在有效控制成本费用的前提下，公司实现营业收入2.02 亿元，并实现商业化运营盈亏平衡目标，超额完成年初目标。APL-1702 的上市申请于 2024 年 5 月获国家药品监督管理局受理后，公司将其上市审评审批工作列为首要目标，重点配置资源全力推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421193630a460f46f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421193630a460f46f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2528055884","title":"亚虹医药（688176）2024年年报简析：营收上升亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2528055884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528055884?lang=zh_cn&edition=full","pubTime":"2025-04-20 06:06","pubTimestamp":1745100414,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亚虹医药发布2024年年报。根据财报显示，亚虹医药营收上升亏损收窄。截至本报告期末，公司营业总收入2.02亿元，同比上升1365.55%，归母净利润-3.84亿元，同比上升4.09%。本次财报公布的各项数据指标表现尚佳。应收款项变动幅度为590.48%,原因:迪派特和欧优比2024年商业化推广稳步推进，销量增加。营业收入变动幅度为1365.55%,原因:公司营业收入主要来自于培唑帕尼片和马来酸奈拉替尼片产生的销售收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042000000497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176"],"gpt_icon":0},{"id":"2528014224","title":"每周股票复盘：亚虹医药（688176）主营收入大幅增长1365.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528014224","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528014224?lang=zh_cn&edition=full","pubTime":"2025-04-19 05:16","pubTimestamp":1745010971,"startTime":"0","endTime":"0","summary":"截至2025年4月18日收盘，亚虹医药-U报收于7.78元，较上周的7.77元上涨0.13%。本周，亚虹医药-U4月14日盘中最高价报8.42元。亚虹医药-U当前最新总市值44.35亿元，在化学制药板块市值排名89/152，在两市A股市值排名2997/5146。本周关注点业绩披露要点: 公司主营收入2.02亿元，同比上升1365.55%业绩披露要点亚虹医药2024年年报显示，公司主营收入2.02亿元，同比上升1365.55%；归母净利润-3.84亿元，同比上升4.09%；扣非净利润-4.09亿元，同比上升5.38%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041900007080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176"],"gpt_icon":0},{"id":"2528062324","title":"亚虹医药(688176.SH)发布2024年度业绩，归母净亏损3.84亿元，亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2528062324","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528062324?lang=zh_cn&edition=full","pubTime":"2025-04-18 21:44","pubTimestamp":1744983870,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)发布2024年年度报告，公司2024年度营业收入2.02亿元，同比增长1,365.55%;归属于上市公司股东的净亏损3.84亿元，亏损收窄;归属于上市公司股东的扣除非经常性损益的净亏损4.09亿元，亏损收窄;基本每股亏损0.68元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1280996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2527215765","title":"亚虹医药收盘下跌2.71%，最新市净率2.17，总市值45.09亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527215765","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527215765?lang=zh_cn&edition=full","pubTime":"2025-04-16 20:10","pubTimestamp":1744805435,"startTime":"0","endTime":"0","summary":"4月16日，亚虹医药今日收盘7.91元，下跌2.71%，最新市净率2.17，总市值45.09亿元。股东方面，截至2024年9月30日，亚虹医药股东户数27825户，较上次减少802户，户均持股市值35.28万元，户均持股数量2.76万股。江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及其它重大疾病领域创新药的研发、生产和销售。最新一期业绩显示，2024年三季报，公司实现营业收入1.39亿元，同比4537.79%；净利润-270840063.46元，同比-1.04%，销售毛利率79.44%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/16201049598427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2527260669","title":"亚虹医药-U涨5.15% 近半年1家券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2527260669","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527260669?lang=zh_cn&edition=full","pubTime":"2025-04-14 10:16","pubTimestamp":1744596969,"startTime":"0","endTime":"0","summary":"04月14日，亚虹医药-U股价大幅上涨，截至10点16分，亚虹医药-U上涨5.15%，报8.17元/股，成交2282万元，换手率0.76%，振幅4.25%。此外，数据统计显示，近半年内1家券商给予买入建议。主营业务及业绩亚虹医药-U公司主营业务为创新药物的研发、生产和销售。最新财报显示，今年三季报，亚虹医药-U实现营业收入1.39亿元，同比增长4537.79%，净利润为-2.71亿元，同比减少1.04%，基本每股收益为-0.48元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041410162794d480fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041410162794d480fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2518429245","title":"亚虹医药-U03月10日主力净流入14万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2518429245","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518429245?lang=zh_cn&edition=full","pubTime":"2025-03-10 15:19","pubTimestamp":1741591171,"startTime":"0","endTime":"0","summary":"03月10日, 亚虹医药-U股价涨0.24%，报收8.39元，成交金额4208万元，换手率1.33%，振幅2.27%，量比0.78。亚虹医药-U今日主力资金净流入14万元，上一交易日主力净流出86万元。该股近5个交易日上涨3.07%，主力资金累计净流入1183万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1385万元，其中净流入天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310154815a26995d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310154815a26995d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2517108359","title":"亚虹医药：公司暂不涉及相关情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2517108359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517108359?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:30","pubTimestamp":1741336256,"startTime":"0","endTime":"0","summary":"证券之星消息，亚虹医药(688176)03月07日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问贵公司是否已经部署了DeepSeek？如果已经部署了，请问主要应用于哪些具体的业务？公司接入DeepSeek有哪些成本、收益方面的考量？如果公司计划在未来再进行部署，计划将DeepSeek应用于什么具体的业务呢？我们投资者非常期待您的回复，谢谢！亚虹医药回复：尊敬的投资者，您好！公司暂不涉及相关情形。感谢您的关注！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030700027631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2517010886","title":"亚虹医药：APL-1702治疗宫颈高级别鳞状上皮内病变患者的上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2517010886","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517010886?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:30","pubTimestamp":1741336251,"startTime":"0","endTime":"0","summary":"证券之星消息，亚虹医药03月07日在投资者关系平台上答复投资者关心的问题。公司于2024年5月公告关于产品APL-1702拟用于治疗18岁及以上排除原位癌的经组织学证实的宫颈高级别鳞状上皮内病变患者的上市申请获得受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030700027611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2517170086","title":"亚虹医药：APL-1702是集药物和器械为一体的光动力治疗产品，以药为主的药械组合产品申请上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2517170086","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517170086?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:30","pubTimestamp":1741336250,"startTime":"0","endTime":"0","summary":"证券之星消息，亚虹医药(688176)03月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，1702获批后，其中的药械部分还需要另外审批吗？生产怎么解决？亚虹医药回复：尊敬的投资者，您好！APL-1702是集药物和器械为一体的光动力治疗产品，以药为主的药械组合产品申请上市。公司拟采用药品上市许可持有人模式，委托有资质的生产企业进行生产。感谢您的关注！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030700027603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1747259860001,"stockEarnings":[{"period":"1week","weight":-0.0289},{"period":"1month","weight":-0.0573},{"period":"3month","weight":0.0872},{"period":"6month","weight":0.0171},{"period":"1year","weight":0.2116},{"period":"ytd","weight":0.1384}],"compareEarnings":[{"period":"1week","weight":0.0183},{"period":"1month","weight":0.0433},{"period":"3month","weight":0.0214},{"period":"6month","weight":0.022},{"period":"1year","weight":0.0821},{"period":"ytd","weight":0.0156}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏亚虹医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24940人(较上一季度减少4.29%)","perCapita":"15167股","listingDate":"2022-01-07","address":"江苏省泰州市海陵区药城大道一号(创业路东侧、园南路北侧)的新药创制基地二期D幢大楼1009房间","registeredCapital":"57000万元","survey":"　　江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域医药的研发、生产和销售。公司的主要产品是抗肿瘤类产品、其他。","listedPrice":22.98},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚虹医药,688176,亚虹医药股票,亚虹医药股票老虎,亚虹医药股票老虎国际,亚虹医药行情,亚虹医药股票行情,亚虹医药股价,亚虹医药股市,亚虹医药股票价格,亚虹医药股票交易,亚虹医药股票购买,亚虹医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}